How many insider trades does FilingIQ track for BLTE?

FilingIQ tracks 119 Form 4 insider transactions for BLTE (BELITE BIO, INC), covering filings from Mar 31, 2026 onwards. 119 of those were filed in the last 90 days.

Are BLTE insiders net buyers or net sellers?

Across the full Form 4 history for BLTE, 0 transactions (0%) were open-market purchases and 112 (94%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does BLTE insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is BLTE in?

BELITE BIO, INC (BLTE) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $6.68B.

BLTE insider trading

NasdaqCM Healthcare

BELITE BIO, INC — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

119

Last 90 days

119

Buys / sells

0% / 94%

Market cap

$6.68B

About BELITE BIO, INC

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an anti-retinol-binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Company website: www.belitebio.com

BLTE insider activity at a glance

FilingIQ has scored 119 insider transactions for BLTE since Mar 31, 2026. The most recent filing in our index is dated May 7, 2026.

Across the full history, 0 open-market purchases and 112 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

View live BLTE trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding BLTE

Atria Wealth Solutions, Inc.

$24.47M · 0.4% of AUM

Frequently asked

How many insider trades does FilingIQ track for BLTE?: FilingIQ tracks 119 Form 4 insider transactions for BLTE (BELITE BIO, INC), covering filings from Mar 31, 2026 onwards. 119 of those were filed in the last 90 days.
Are BLTE insiders net buyers or net sellers?: Across the full Form 4 history for BLTE, 0 transactions (0%) were open-market purchases and 112 (94%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does BLTE insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is BLTE in?: BELITE BIO, INC (BLTE) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $6.68B.

Methodology & sources

Every BLTE insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.